Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

February 7, 2017

Conditions
NSCLC
Interventions
DRUG

Icotinib

Icotinib: 125 mg is administered orally three times per day.

DRUG

Chemotherapy

First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.

Trial Locations (21)

100853

Chinese People's Liberation Army (PLA) General Hospital, Beijing

101149

Beijing Hospital for Chest Tumors & Tuberculosis Diseases, Beijing

110001

Harbin Medical Univercity Cancer Hospital, Harbin

The First Hospital of China Medical University, Shenyang

130021

The First Bethune Hospital of Jilin Univercity, Changchun

200030

Shanghai Chest Hospital Affiliated to Shanghai Jiaotong Univercity, Shanghai

200032

Zhongshan Hospital Affiliated to Fudan Univercity, Shanghai

200433

Changhai Hospital, The Second Military Medical University, Shanghai

210009

Jiangsu Cancer Hospital, Nanjing

210029

Jiangsu Provincal Tumor Hospital, Nanjing

230022

The First Affiliated Hospital of Anhui Medical Univercity, Hefei

250117

Shandong Cancer Hospital, Jinan

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

400037

Xinqiao Hospital, The Third Military Medical University, Chongqing

450003

Henan Provincal Tumor Hospital, Zhengzhou

510120

The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou

510515

Nanfang Hospital, Southern Medical University, Guangzhou

610041

Sichuan Provincal Tumor Hospital, Chengdu

West China Hospital, Sichuan University, Chengdu

710032

Xijing Hospital, Xian

050011

Hebei Provincal Tumor Hospital, Shijiazhuang

All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY